Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Latin American Cooperative Oncology Group
With
Brazilian Breast Cancer Study Group (GBECAM)
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women ≥18 years old
Histologically confirmed hormone receptor-positive HER2-negative invasive breast cancer
Hormone receptor-positive defined as 1% to 100% of tumor nuclei positive for Estrogen - - Receptor and/or Progesterone Receptor, as per ASCO/CAP Guideline 2020 - or Allred score of ≥3
HER2-negative defined as IHC result is 0/1+ or 2+ with ISH negative as per ASCO/CAP Guideline 2018
Diagnosed with de novo or recurrent metastatic breast cancer between January 2018 -and December 2020
Public health system or private health system
You may not be if
Male Breast Cancer
First-line treatment for mBC received through clinical trial
Clareo Health | Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil
